We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Phoqus | LSE:PQS | London | Ordinary Share | GB00B0M4CD64 | ORD 10P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 8.00 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
RNS Number:6805C Phoqus Group plc 23 August 2007 Notice of EGM to change name of Phoqus Group plc to Phoqus Pharmaceuticals plc West Malling, UK, 23 August 2007: Phoqus Group plc (AIM: PQS) ("Phoqus" or "Company"), the specialty pharmaceuticals drug development company, today announces that it has convened an extraordinary general meeting ("EGM") of the Company to approve the Board's proposal to change the Company's name to Phoqus Pharmaceuticals plc. In July 2007, the Company successfully concluded a Placing raising #5.2 million to fund its new strategy as a specialty pharmaceutical drug development company focused on the development of new therapeutic products for patients with significant unmet medical needs. The net proceeds of the Placing will allow the Company to continue the development of its lead product Chronocort(TM), with a view to maximising value for shareholders. In order to reflect this new strategy, the Board has decided that it is appropriate to change the name of the Company from Phoqus Group plc to Phoqus Pharmaceuticals plc. A notice has been sent to shareholders today convening an EGM at the Company's registered office at 10:30 am on 18 September 2007 at which the proposal to change the Company's name will be put to shareholders. The proposed new name is currently used by the Company's trading subsidiary, Phoqus Pharmaceuticals Ltd, and is already in daily use as a trading name of the subsidiary, for example on the website. The name of the subsidiary will itself change to Phoqus Pharmaceuticals (UK) Ltd. Enquiries: Phoqus Group plc Tel: 01732 870227 Dr Richard Mason, CEO Dr Peter Johnson, CFO Financial Dynamics Tel: 020 7831 3113 David Yates/John Gilbert Nomura Code Securities Limited Tel: 020 7776 1200 Phil Walker Notes to Editors About Chronocort(TM) Chronocort(TM) is the first circadian endocrine treatment for congenital adrenal hyperplasia ("CAH") and adrenal insufficiency ("AI"). Chronocort(TM) uses Phoqus' proprietary Qtrol(TM) modified release technology to provide a delayed- and-sustained release profile of hydrocortisone to mimic the natural over-night and early morning hormone levels found in healthy individuals that are considered important in controlling both actual disease symptoms and also reducing unwanted side effects resulting from excess steroid treatment. Chronocort(TM) has successfully completed a number of phase I clinical studies and planning is underway for the full clinical development programme which includes pivotal pre-registration studies in both CAH patients and patients suffering from AI. Phoqus appointed a medical advisory board at the beginning of 2007 comprising leading endocrinologists from Europe and the USA to assist the Company in the design of the clinical development programmes able to demonstrate patient benefits and clinical superiority of Chronocort(TM) over existing therapies for both CAH and AI. Some of the underlying intellectual property supporting the Chronocort(TM) product is licensed from Diurnal Limited, a spin-out from the University of Sheffield financed by Biofusion plc. Phoqus and Diurnal collaborate on certain aspects of Chronocort(TM)'s development. About Phoqus Phoqus is a speciality pharmaceutical drug development company developing secondary care products for patients with significant unmet medical needs through the use of its proprietary drug delivery and re-formulation technologies. These allow the company to change the pharmacokinetic profile of drugs, either improving their therapeutic effect (efficacy and/or safety) in existing indications, or to change their therapeutic effect so that they may find use in new indications. Phoqus' core capability is in oral drug delivery and it has combined its technology platform with expertise in formulating tablets and tablet coat powders to create a range of innovative and diverse drug delivery applications. The Phoqus technology is protected by a substantial patent portfolio. Phoqus' underlying technology platform is based upon electrostatic dry powder deposition. This process deposits charged powder particles on to the surface of a substrate with high precision. Based in Kent, Phoqus was established in 1998 and was admitted to trading on AIM in November 2005. It is listed under the symbol "PQS". Further background on the Company can be found at www.phoqus.com. This information is provided by RNS The company news service from the London Stock Exchange END NOEEADPAAAPXEAE
1 Year Phoqus Chart |
1 Month Phoqus Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions